Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Tan Sheet

Executive Summary

Bausch & Lomb: New chairman and CEO Ronald Zarrella plans to lower firm's SG&A expenses, increase R&D and trim personnel based on results of comprehensive talent review, he announces during a conference call Dec. 3. Zarrella also notes B&L has been "under-funding lens care, and while it is a very slow- to no-growth business, we have got a dominant position, a terrific brand and it generates an awful lot of money. I think we ought to be paying a little bit more attention to that." Company's lens care sales fell 7.7% to $118.3 mil. in Q3 (1"The Tan Sheet" Oct. 22, p. 7). Zarrella took over at B&L in mid-November; he will provide a more detailed description of his goals Jan. 4...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093371

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel